Cargando…
A Novel and Selective Poly (ADP-Ribose) Polymerase Inhibitor Ameliorates Chemotherapy-Induced Painful Neuropathy
BACKGROUND: Chemotherapy-induced neuropathy is the principle dose limiting factor requiring discontinuation of many chemotherapeutic agents, including cisplatin and oxaliplatin. About 30 to 40% of patients receiving chemotherapy develop pain and sensory changes. Given that poly (ADP-ribose) polymera...
Autores principales: | Ta, Lauren E., Schmelzer, James D., Bieber, Allan J., Loprinzi, Charles L., Sieck, Gary C., Brederson, Jill D., Low, Philip A., Windebank, Anthony J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542321/ https://www.ncbi.nlm.nih.gov/pubmed/23326593 http://dx.doi.org/10.1371/journal.pone.0054161 |
Ejemplares similares
-
Poly (ADP-Ribose) Polymerase Mediates Diabetes-Induced Retinal Neuropathy
por: Mohammad, Ghulam, et al.
Publicado: (2013) -
RNA regulation by Poly(ADP-ribose) polymerases
por: Bock, Florian J., et al.
Publicado: (2015) -
Mitotic functions of poly(ADP-ribose) polymerases
por: Slade, Dea
Publicado: (2019) -
The Antiviral Activities of Poly-ADP-Ribose Polymerases
por: Malgras, Mathilde, et al.
Publicado: (2021) -
Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma
por: Vormoor, Britta, et al.
Publicado: (2014)